119 related articles for article (PubMed ID: 37698225)
21. Identification of a novel cuproptosis-related gene signature and integrative analyses in patients with lower-grade gliomas.
Bao JH; Lu WC; Duan H; Ye YQ; Li JB; Liao WT; Li YC; Sun YP
Front Immunol; 2022; 13():933973. PubMed ID: 36045691
[TBL] [Abstract][Full Text] [Related]
22. The role of a cuproptosis-related prognostic signature in colon cancer tumor microenvironment and immune responses.
Xu C; Liu Y; Zhang Y; Gao L
Front Genet; 2022; 13():928105. PubMed ID: 36313449
[No Abstract] [Full Text] [Related]
23. A Prognostic Cuproptosis-Related LncRNA Signature for Colon Adenocarcinoma.
Zhong L; Zhu J; Shu Q; Xu G; He C; Fang L
J Oncol; 2023; 2023():5925935. PubMed ID: 36844874
[TBL] [Abstract][Full Text] [Related]
24. Characterization of a cuproptosis-related signature to evaluate immune features and predict prognosis in colorectal cancer.
Li L; Sun F; Kong F; Feng Y; Song Y; Du Y; Liu F; Kong X
Front Oncol; 2023; 13():1083956. PubMed ID: 37384293
[TBL] [Abstract][Full Text] [Related]
25. Cuproptosis-related genes signature and validation of differential expression and the potential targeting drugs in temporal lobe epilepsy.
Yang X; Zhang X; Shen K; Wang Z; Liu G; Huang K; He Z; Li Y; Hou Z; Lv S; Zhang C; Yang H; Liu S; Ke Y
Front Pharmacol; 2023; 14():1033859. PubMed ID: 37435496
[No Abstract] [Full Text] [Related]
26. Development and validation of cuproptosis-related lncRNAs associated with pancreatic cancer immune microenvironment based on single-cell.
Sun Y; Yao L; Man C; Gao Z; He R; Fan Y
Front Immunol; 2023; 14():1220760. PubMed ID: 37822927
[TBL] [Abstract][Full Text] [Related]
27. Identification of two molecular subtypes and a novel prognostic model of lung adenocarcinoma based on a cuproptosis-associated gene signature.
Zhou J; Chen D; Zhang S; Wang C; Zhang L
Front Genet; 2022; 13():1039983. PubMed ID: 36712848
[TBL] [Abstract][Full Text] [Related]
28. A cuproptosis-related lncRNA signature to predict prognosis and immune microenvironment of colon adenocarcinoma.
Li D; Qu G; Ling S; Sun Y; Cui Y; Yang Y; Cao X
Sci Rep; 2023 Apr; 13(1):6284. PubMed ID: 37072493
[TBL] [Abstract][Full Text] [Related]
29. Cuproptosis-related prognostic signatures predict the prognosis and immunotherapy in HCC patients.
Peng H; Zou Z; Xiang Z; Lu X; Zhang Y; Peng X
Medicine (Baltimore); 2023 Aug; 102(34):e34741. PubMed ID: 37653738
[TBL] [Abstract][Full Text] [Related]
30. Cuproptosis-Related Genes Are Associated with Cell Cycle and Serve as the Prognostic Signature for Clear Cell Renal Cell Carcinoma.
Guo T; Zhang J; Yuan Z; Tang H; Wang T; Wang X; Chen S
J Clin Med; 2022 Dec; 11(24):. PubMed ID: 36556123
[TBL] [Abstract][Full Text] [Related]
31. A novel signature model based on mitochondrial-related genes for predicting survival of colon adenocarcinoma.
Gao H; Xing F
BMC Med Inform Decis Mak; 2022 Oct; 22(1):277. PubMed ID: 36273131
[TBL] [Abstract][Full Text] [Related]
32. A novel enterocyte-related 4-gene signature for predicting prognosis in colon adenocarcinoma.
Cheng X; Wei Y; Fu Y; Li J; Han L
Front Immunol; 2022; 13():1052182. PubMed ID: 36532007
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive analysis of a cuproptosis-related ceRNA network implicates a potential endocrine therapy resistance mechanism in ER-positive breast cancer.
Zhang D; Lu W; Zhuo Z; Wang Y; Zhang W; Zhang M
BMC Med Genomics; 2023 May; 16(1):96. PubMed ID: 37143115
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive analysis of cuproptosis-related long noncoding RNA for predicting prognostic and diagnostic value and immune landscape in colorectal adenocarcinoma.
Liu S; Zhang S; Liu Y; Yang X; Zheng G
Hum Genomics; 2023 Mar; 17(1):22. PubMed ID: 36915193
[TBL] [Abstract][Full Text] [Related]
35. Cuproptosis Related Gene DLD Associated with Poor Prognosis and Malignant Biological Characteristics in Lung Adenocarcinoma.
Li X; Rui J; Yang Z; Shang-Guan F; Shi H; Wang D; Sun J
Curr Cancer Drug Targets; 2024 Jan; ():. PubMed ID: 38310466
[TBL] [Abstract][Full Text] [Related]
36. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
[TBL] [Abstract][Full Text] [Related]
37. System analysis based on the cuproptosis-related genes identifies LIPT1 as a novel therapy target for liver hepatocellular carcinoma.
Yan C; Niu Y; Ma L; Tian L; Ma J
J Transl Med; 2022 Oct; 20(1):452. PubMed ID: 36195876
[TBL] [Abstract][Full Text] [Related]
38. Construction of a prognostic model based on genes associated with mitochondrial energy metabolic pathway in colon adenocarcinoma and its clinical significance.
Zhang X; Liang C; Zhou B; Pang L
J Mol Recognit; 2023 Aug; 36(8):e3044. PubMed ID: 37322568
[TBL] [Abstract][Full Text] [Related]
39. Construction of a novel choline metabolism-related signature to predict prognosis, immune landscape, and chemotherapy response in colon adenocarcinoma.
Liu C; Liu D; Wang F; Liu Y; Xie J; Xie J; Xie Y
Front Immunol; 2022; 13():1038927. PubMed ID: 36451813
[TBL] [Abstract][Full Text] [Related]
40. Based on cuproptosis-related lncRNAs, a novel prognostic signature for colon adenocarcinoma prognosis, immunotherapy, and chemotherapy response.
Li C; Zhang K; Gong Y; Wu Q; Zhang Y; Dong Y; Li D; Wang Z
Front Pharmacol; 2023; 14():1200054. PubMed ID: 37377924
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
